We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

48 hedge funds and large institutions have $59.7M invested in Ovid Therapeutics in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

82% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 11

20% more capital invested

Capital invested by funds: $49.8M → $59.7M (+$9.87M)

2.43% more ownership

Funds ownership: 28.65% → 31.09% (+2.4%)

0% more funds holding

Funds holding: 48 → 48 (0)

0% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 9

Holders
48
Holders Change
–
Holders Change %
0%
% of All Funds
1.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
20
Reduced
11
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CI
Cowen Inc
New York
+$5.69M
2
GPCM
Granite Point Capital Management
Massachusetts
+$2.29M
3
BlackRock
BlackRock
New York
+$1.03M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$380K
5
State Street
State Street
Massachusetts
+$301K

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$2.2M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$993K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$612K
4
Millennium Management
Millennium Management
New York
-$380K
5
RG
Redmile Group
California
-$333K

OVID Hedge Fund Activity: Q2 2018 in Review

48 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q2 2018, worth a combined $59.7M — up 20% from $49.8M a quarter earlier.

Fund positioning in OVID was balanced in Q2 2018: 9 funds opened new positions, 9 closed out, 20 added to existing stakes and 11 trimmed.

The largest buyer was Cowen Inc, opening a new position worth an estimated $5.69M. The largest seller was Jennison Associates, cutting an estimated $2.2M.

  • 48 institutional investors held Ovid Therapeutics (OVID) as of Q2 2018, unchanged from Q1 2018.
  • Funds reported $59.7M of Ovid Therapeutics stock for Q2 2018, up 20% quarter-over-quarter.
  • 9 funds opened new Ovid Therapeutics positions in Q2 2018 and 9 closed out, a net change of 0 holders.
  • The largest Ovid Therapeutics buyer in Q2 2018 was Cowen Inc, an estimated $5.69M added.
  • The largest Ovid Therapeutics seller in Q2 2018 was Jennison Associates, an estimated $2.2M sold.

Based on aggregated 13F filings for Q2 2018.